Key points are not available for this paper at this time.
Approximately 200 000 patients have been treated with rituximab, yet the debate over the relative importance of various potential mechanisms of action for this antibody continues. In this issue, Cragg and colleagues (page 10451) report on complement-mediated cytotoxicity induced by various
George J. Weiner (Wed,) studied this question.